Design and preclinical evaluation of a first-in-class covalent reversible inhibitor of IRAK4 with immunomodulatory properties and selective anti-lymphoma effect

Gema Gorjon de Pablo; Nuria Profitos-Peleja; Miek Jacobs; Aitor Gonzalez-Herrero; Jeronimo Parra; Elisabetta Mereu; Paula Cifuentes; Melissa Orphali; Jordi Teixidó Closa; Manel Esteller; Jose I. Borrell; Roger Estrada-Tejedor; Gael Roue

doi:10.1158/1538-7445.AM2025-6160

Design and preclinical evaluation of a first-in-class covalent reversible inhibitor of IRAK4 with immunomodulatory properties and selective anti-lymphoma effect

Gema Gorjon de Pablo
, Nuria Profitos-Peleja
, Miek Jacobs
, Aitor Gonzalez-Herrero
, Jeronimo Parra
, Elisabetta Mereu
, Paula Cifuentes
, Melissa Orphali
, Jordi Teixidó Closa
, Manel Esteller
, Jose I. Borrell
, Roger Estrada-Tejedor
, Gael Roue

Research output: Indexed journal article › Meeting Abstract › peer-review

Original language	English
Number of pages	2
Journal	Cancer Research
Volume	85
Issue number	8
DOIs	https://doi.org/10.1158/1538-7445.AM2025-6160
Publication status	Published - 15 Apr 2025
Event	Annual Meeting of the American-Association-for-Cancer-Research (AACR) - Chicago, Israel Duration: 25 Apr 2025 → 30 Apr 2025

Access to Document

10.1158/1538-7445.AM2025-6160

Cite this

de Pablo, G. G., Profitos-Peleja, N., Jacobs, M., Gonzalez-Herrero, A., Parra, J., Mereu, E., Cifuentes, P., Orphali, M., Teixidó Closa, J., Esteller, M., Borrell, J. I., Estrada-Tejedor, R., & Roue, G. (2025). Design and preclinical evaluation of a first-in-class covalent reversible inhibitor of IRAK4 with immunomodulatory properties and selective anti-lymphoma effect. Cancer Research, 85(8). https://doi.org/10.1158/1538-7445.AM2025-6160

@article{6d7bd96847da457b975cb664d68ddd99,

title = "Design and preclinical evaluation of a first-in-class covalent reversible inhibitor of IRAK4 with immunomodulatory properties and selective anti-lymphoma effect",

author = "\{de Pablo\}, \{Gema Gorjon\} and Nuria Profitos-Peleja and Miek Jacobs and Aitor Gonzalez-Herrero and Jeronimo Parra and Elisabetta Mereu and Paula Cifuentes and Melissa Orphali and \{Teixid{\'o} Closa\}, Jordi and Manel Esteller and Borrell, \{Jose I.\} and Roger Estrada-Tejedor and Gael Roue",

year = "2025",

month = apr,

day = "15",

doi = "10.1158/1538-7445.AM2025-6160",

language = "English",

volume = "85",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "8",

note = "Annual Meeting of the American-Association-for-Cancer-Research (AACR) ; Conference date: 25-04-2025 Through 30-04-2025",

}

de Pablo, GG, Profitos-Peleja, N, Jacobs, M, Gonzalez-Herrero, A, Parra, J, Mereu, E, Cifuentes, P, Orphali, M , Teixidó Closa, J, Esteller, M, Borrell, JI , Estrada-Tejedor, R & Roue, G 2025, 'Design and preclinical evaluation of a first-in-class covalent reversible inhibitor of IRAK4 with immunomodulatory properties and selective anti-lymphoma effect', Cancer Research, vol. 85, no. 8. https://doi.org/10.1158/1538-7445.AM2025-6160

TY - JOUR

T1 - Design and preclinical evaluation of a first-in-class covalent reversible inhibitor of IRAK4 with immunomodulatory properties and selective anti-lymphoma effect

AU - de Pablo, Gema Gorjon

AU - Profitos-Peleja, Nuria

AU - Jacobs, Miek

AU - Gonzalez-Herrero, Aitor

AU - Parra, Jeronimo

AU - Mereu, Elisabetta

AU - Cifuentes, Paula

AU - Orphali, Melissa

AU - Teixidó Closa, Jordi

AU - Esteller, Manel

AU - Borrell, Jose I.

AU - Estrada-Tejedor, Roger

AU - Roue, Gael

PY - 2025/4/15

Y1 - 2025/4/15

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_univeritat_ramon_llull&SrcAuth=WosAPI&KeyUT=WOS:001500371004310&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1158/1538-7445.AM2025-6160

DO - 10.1158/1538-7445.AM2025-6160

M3 - Meeting Abstract

SN - 0008-5472

VL - 85

JO - Cancer Research

JF - Cancer Research

IS - 8

T2 - Annual Meeting of the American-Association-for-Cancer-Research (AACR)

Y2 - 25 April 2025 through 30 April 2025

ER -

Design and preclinical evaluation of a first-in-class covalent reversible inhibitor of IRAK4 with immunomodulatory properties and selective anti-lymphoma effect

Access to Document

Other files and links

Cite this